Publications by authors named "Huo-Ping Zhang"
Article Synopsis
- NAFLD is closely linked to type 2 diabetes (T2DM), and lifestyle changes are preferred treatments, but there's limited research on combining new glucose-lowering medications, semaglutide (a GLP-1 receptor agonist) and empagliflozin (an SGLT-2 inhibitor), for these patients.
- This trial involves 105 overweight/obese participants and will last 52 weeks, comparing the effects of each drug alone and together on various health indicators, including liver health and blood sugar levels.
- Findings from this study could shed light on the benefits of using both medications together in treating NAFLD associated with T2DM.
View Article and Find Full Text PDF